BRPI1010970A2 - solução farmacêutica, processo para preparar uma solução farmacêutica e método para tratamento - Google Patents

solução farmacêutica, processo para preparar uma solução farmacêutica e método para tratamento

Info

Publication number
BRPI1010970A2
BRPI1010970A2 BRPI1010970-6A BRPI1010970A BRPI1010970A2 BR PI1010970 A2 BRPI1010970 A2 BR PI1010970A2 BR PI1010970 A BRPI1010970 A BR PI1010970A BR PI1010970 A2 BRPI1010970 A2 BR PI1010970A2
Authority
BR
Brazil
Prior art keywords
pharmaceutical solution
preparing
treating
pharmaceutical
solution
Prior art date
Application number
BRPI1010970-6A
Other languages
English (en)
Inventor
Sanjay Motwani Kumar
P. Isloor Sashikanth
Arora Vinod
Original Assignee
Ranbaxy Laboratories Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ranbaxy Laboratories Limited filed Critical Ranbaxy Laboratories Limited
Publication of BRPI1010970A2 publication Critical patent/BRPI1010970A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/203—Retinoic acids ; Salts thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/07—Retinol compounds, e.g. vitamin A
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Physiology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Nutrition Science (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurology (AREA)
  • Pulmonology (AREA)
  • Pain & Pain Management (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

solução farmacêutica, processo para preparar uma solução farmacêutica e método para tratamento a presente invenção refere-se a uma solução farmacêutica que compreende isotretinoina ou sais da mesma. a presente invenção se refere adicionalmente aos processos para preparar tais composições.
BRPI1010970-6A 2009-05-20 2010-05-20 solução farmacêutica, processo para preparar uma solução farmacêutica e método para tratamento BRPI1010970A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
IN1039/DEL/2009 2009-05-20
IN1039DE2009 2009-05-20
PCT/IB2010/052254 WO2010134047A2 (en) 2009-05-20 2010-05-20 Liquid dosage forms of isotretinoin

Publications (1)

Publication Number Publication Date
BRPI1010970A2 true BRPI1010970A2 (pt) 2019-04-09

Family

ID=54261167

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI1010970-6A BRPI1010970A2 (pt) 2009-05-20 2010-05-20 solução farmacêutica, processo para preparar uma solução farmacêutica e método para tratamento

Country Status (8)

Country Link
US (2) US20120259013A1 (pt)
EP (1) EP2432553A2 (pt)
CN (1) CN102802729A (pt)
BR (1) BRPI1010970A2 (pt)
CA (1) CA2762391C (pt)
MX (1) MX2011012232A (pt)
SG (2) SG176096A1 (pt)
WO (1) WO2010134047A2 (pt)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7435427B2 (en) 2000-09-22 2008-10-14 Galephar M/F Pharmaceutical semi-solid composition of isotretinoin
US9138786B2 (en) * 2008-10-17 2015-09-22 Foro Energy, Inc. High power laser pipeline tool and methods of use
US9244235B2 (en) 2008-10-17 2016-01-26 Foro Energy, Inc. Systems and assemblies for transferring high power laser energy through a rotating junction
SG176097A1 (en) 2009-05-20 2011-12-29 Ranbaxy Lab Ltd Topical retinoid solutions
US9078925B2 (en) 2012-06-18 2015-07-14 Galephar Pharmaceutical Research, Inc. Pharmaceutical semi-solid composition of isotretinoin
WO2014070767A1 (en) 2012-10-29 2014-05-08 Arizona Board Of Regents On Behalf Of University Of Arizona Predictive markers for polyamine inhibitor cancer therapies
EP3148644A4 (en) 2014-05-29 2017-12-20 Sun Pharmaceutical Industries Ltd Oral pharmaceutical composition of isotretinoin
RU2016150868A (ru) * 2014-06-02 2018-07-17 Сан Фармасьютикал Индастриз Лимитед Пероральная фармацевтическая композиция изотретиноина
WO2015195120A1 (en) 2014-06-18 2015-12-23 Arizona Board Of Regents On Behalf Of University Of Arizona Carcinoma diagnosis and treatment based on odc1 genotype
MA40447A (fr) 2014-07-31 2016-02-04 Sun Pharmaceutical Ind Ltd Composition pharmaceutique orale d'isotrétinoïne
US9750711B2 (en) * 2014-10-01 2017-09-05 Sun Pharmaceutical Industries Limited Low dose oral pharmaceutical composition of isotretinoin
US20190046484A1 (en) * 2015-02-12 2019-02-14 Arizona Board Of Regents On Behalf Of The University Of Arizona Methods for treating neuroblastoma
BR112018008556A2 (pt) * 2015-10-30 2018-10-23 Patagonia Pharmaceuticals Llc ?composições farmacêuticas e métodos para tratar ictiose congênita?
EP3368029A1 (en) 2015-10-30 2018-09-05 Cancer Prevention Pharmaceuticals, Inc. Eflornithine and sulindac, fixed dose combination formulation
EP3968971A1 (en) 2019-05-17 2022-03-23 Cancer Prevention Pharmaceuticals, Inc. Methods for treating familial adenomatous polyposis
EP4236915A4 (en) * 2020-11-01 2024-10-23 Idrs Labs Pvt Ltd ORAL LIQUID PHARMACEUTICAL COMPOSITIONS OF ISOTRETINOIN
MA69876A1 (fr) 2022-07-01 2025-11-28 Acrotech Biopharma Inc. Compositions pharmaceutiques comprenant de l'isotrétinoïne ainsi que leurs procédés de préparation et leurs utilisations
CN119033671B (zh) * 2024-09-05 2025-04-04 中南大学湘雅三医院 一种异维a酸油剂及其制备方法和应用

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4322438A (en) 1979-08-06 1982-03-30 United States Of America Method for the use of orally administered 13-cis-retinoic acid in the treatment of acne
CA1282326C (en) 1984-12-14 1991-04-02 Paul J. Jarosz Pharmaceutical composition containing 13-cis vitamin a acid as the active ingredient
PE20001227A1 (es) * 1998-10-30 2000-11-06 Hoffmann La Roche Procesos para producir una composicion de isotretinoina
US6339107B1 (en) * 2000-08-02 2002-01-15 Syntex (U.S.A.) Llc Methods for treatment of Emphysema using 13-cis retinoic acid
US7435427B2 (en) 2000-09-22 2008-10-14 Galephar M/F Pharmaceutical semi-solid composition of isotretinoin
FR2818905A1 (fr) * 2000-12-28 2002-07-05 Cll Pharma Compositions pharmaceutiques colloidales micellaires renfermant un principe actif lipophile
US20060241078A1 (en) * 2005-03-16 2006-10-26 Ahmed Salah U Pharmaceutical compositions comprising a contraceptive agent in solution and a teratogen
CA2626579A1 (en) * 2005-10-25 2007-05-03 Abbott Laboratories Formulation comprising a drug of low water solubility and method of use thereof

Also Published As

Publication number Publication date
US20170165217A1 (en) 2017-06-15
US20120259013A1 (en) 2012-10-11
WO2010134047A2 (en) 2010-11-25
WO2010134047A3 (en) 2011-11-24
MX2011012232A (es) 2012-04-10
SG2014011969A (en) 2014-09-26
SG176096A1 (en) 2011-12-29
EP2432553A2 (en) 2012-03-28
CA2762391A1 (en) 2010-11-25
CN102802729A (zh) 2012-11-28
CA2762391C (en) 2017-02-07

Similar Documents

Publication Publication Date Title
BRPI1010970A2 (pt) solução farmacêutica, processo para preparar uma solução farmacêutica e método para tratamento
BR112017009701A2 (pt) composto e métodos para a preparação de um composto
BRPI0924136A8 (pt) Composição farmacêutica sólida compreendendo amlodipina e losartan e método para a preparação da mesma
BR112014003296A2 (pt) composto, composição farmacêutica, processo para a preparação de uma composição farmacêutica, método para o tratamento de uma doença ou distúrbio, conjunto para o tratamento de uma condição mediada pela quinase pim e utilização do composto
BR112017021167A2 (pt) composto, método de tratamento de câncer, e processo para preparar o composto de fórmula i
BR112014024180A2 (pt) copolímero de poliorganossiloxano linear, processo para a fabricação de copolímero de poliorganossiloxano linear, composições de poliorganossiloxano, emulsões aquosas, métodos de tratamento de superfície e processo para a fabricação de uma composição
BR112017019287A2 (pt) composto, composição farmaceuticamente aceitável, método de tratamento de câncer, processo para preparar o composto da fórmula i, método para tratar câncer, e kit
CL2014002077A1 (es) Composicion farmaceutica que comprende fumarato de dimetilo; metodo de preparacion; capsula que comprende microtabletas de fumarato de dimetilo; metodo para el tratamiento, profilaxis o mejora de la esclerosis multiple.
BRPI0908421B8 (pt) solução estável de um composto farmacêutico
BR112016029612A2 (pt) compostos de di-hidroisoquinolinona substituídos
CR20140052A (es) Un derivado novedoso de 1,2,3,4-tetrahidroquinolina útil para el tratamiento de diabetes
BR112015006393A2 (pt) método para produzir um produto de tecido, produto de tecido produzido por um processo, e método de tratamento
MX2014005342A (es) Inhibidores del virus de la hepatitis c.
BR112019006530A2 (pt) processo de purificação de óleo
BRPI0922774B8 (pt) composto cloridrato de nelmefeno di-hidratado, sua composição farmacêutica e processos de obtenção e produção dos mesmos.
BR112017007144A2 (pt) ácido valproico ou um sal farmaceuticamente aceitável do mesmo, composto, composição farmacêutica, e, composto ou composição para uso, uso, método ou composição.
CY1123438T1 (el) Διαδικασια για παραγωγη και καθαρισμοανασυνδυασμενης λυσοσωμικης αλφα-μαννοσιδασης
BR112012020078A2 (pt) composição de tratamento de roupa método de tratamento de um produto têxtil de roupa
EA201491286A1 (ru) Способ лечения потери костной массы альвеолярного отростка посредством применения антител к склеростину
BR112015002493A2 (pt) composto , composição farmacêutica , método para o tratamento do câncer , processo para a preparação de uma composição farmacêutica , conjunto , utilização de um composto e invenção.
BRPI1007433A2 (pt) método para tratar um substrato de carpete, composição de tratamento para conferir propriedades antimicrobianas duráveis a um carpete, e, produto de carpete.
BR112016028316A2 (pt) composição farmacêutica oral de isotretinoina, seu processo de preparação e método de tratamento
BR112018006545A2 (pt) ?composto, composição farmacêutica, combinação, uso de um composto, e, método para tratamento de uma doença ou condição?
BR112015007843A2 (pt) método para a preparação de um polímero, polímero, artigo e método de preparação de um artigo
BR112017003663A2 (pt) composto, composição, e, método para tratamento de infecção por hiv.

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE AS 7A, 8A E 9A ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2519 DE 16-04-2019 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.

B350 Update of information on the portal [chapter 15.35 patent gazette]